Stephanie A Curreri1, Chunkit Fung2, Clair J Beard3. 1. Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Electronic address: scurreri@lroc.harvard.edu. 2. University of Rochester Medical Center, Rochester, NY. 3. Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Abstract
BACKGROUND: Testicular cancer is the most common cancer among men aged 15 to 40 years, and the incidence of testicular cancer is steadily increasing. Despite successful treatment outcomes and the rate of survival at 5 to 10 years being 95%, survivors can experience late effects of both their cancer and the treatment they received, including secondary malignant neoplasms (SMNs). We discuss the development of non-germ cell SMNs that develop after diagnosis and treatment of testicular cancer and their effect on mortality. RESULTS: Patients diagnosed with testicular cancer frequently choose postoperative surveillance if they are diagnosed with clinical stage I disease. These patients may experience an increased risk for developing SMNs following radiation exposure from diagnostic imaging. Similarly, radiotherapy for testicular cancer is associated with increased risks of developing both solid tumors and leukemia. Studies have reported that patients exposed to higher doses of radiation have an increased risk of developing SMNs when compared with patients who received lower doses of radiation. Patients treated with chemotherapy also experience an increased risk of developing SMNs following testicular cancer, though the risk following chemotherapy and radiation therapy combined is not well described. A large population-based study concluded that the rate ratios for both cancer-specific and all-cause mortality for SMNs among testicular cancer survivors were not significantly different from those of matched first cancers. CONCLUSIONS: Although it is known that patients who receive adjuvant chemotherapy or radiotherapy or who undergo routine diagnostic or follow-up imaging for a primary testicular cancer are at an increased risk for developing SMNs, the extent of this risk is largely unknown. It is critically important that research be conducted to determine this risk and its contributing factors as accurately as possible.
BACKGROUND:Testicular cancer is the most common cancer among men aged 15 to 40 years, and the incidence of testicular cancer is steadily increasing. Despite successful treatment outcomes and the rate of survival at 5 to 10 years being 95%, survivors can experience late effects of both their cancer and the treatment they received, including secondary malignant neoplasms (SMNs). We discuss the development of non-germ cell SMNs that develop after diagnosis and treatment of testicular cancer and their effect on mortality. RESULTS:Patients diagnosed with testicular cancer frequently choose postoperative surveillance if they are diagnosed with clinical stage I disease. These patients may experience an increased risk for developing SMNs following radiation exposure from diagnostic imaging. Similarly, radiotherapy for testicular cancer is associated with increased risks of developing both solid tumors and leukemia. Studies have reported that patients exposed to higher doses of radiation have an increased risk of developing SMNs when compared with patients who received lower doses of radiation. Patients treated with chemotherapy also experience an increased risk of developing SMNs following testicular cancer, though the risk following chemotherapy and radiation therapy combined is not well described. A large population-based study concluded that the rate ratios for both cancer-specific and all-cause mortality for SMNs among testicular cancer survivors were not significantly different from those of matched first cancers. CONCLUSIONS: Although it is known that patients who receive adjuvant chemotherapy or radiotherapy or who undergo routine diagnostic or follow-up imaging for a primary testicular cancer are at an increased risk for developing SMNs, the extent of this risk is largely unknown. It is critically important that research be conducted to determine this risk and its contributing factors as accurately as possible.
Authors: Marie C Hupe; Marie C Hempel; Severin Rodler; Maria Frantzi; Harald Mischak; Axel S Merseburger; Christian G Stief; Michael Chaloupka Journal: Urologe A Date: 2021-06-22 Impact factor: 0.639
Authors: João Lobo; Ana Laura Costa; Mariana Cantante; Rita Guimarães; Paula Lopes; Luís Antunes; Isaac Braga; Jorge Oliveira; Mattia Pelizzola; Rui Henrique; Carmen Jerónimo Journal: J Transl Med Date: 2019-03-12 Impact factor: 5.531
Authors: João Lobo; Ad J M Gillis; Annette van den Berg; Lambert C J Dorssers; Gafanzer Belge; Klaus-Peter Dieckmann; Henk P Roest; Luc J W van der Laan; Jourik Gietema; Robert J Hamilton; Carmen Jerónimo; Rui Henrique; Daniela Salvatori; Leendert H J Looijenga Journal: Cells Date: 2019-12-14 Impact factor: 6.600
Authors: João Lobo; Ana Rita Cardoso; Vera Miranda-Gonçalves; Leendert H J Looijenga; Marie Lopez; Paola B Arimondo; Rui Henrique; Carmen Jerónimo Journal: Pharmaceutics Date: 2021-01-07 Impact factor: 6.321
Authors: Margaret Ottaviano; Emilio Francesco Giunta; Pasquale Rescigno; Ricardo Pereira Mestre; Laura Marandino; Marianna Tortora; Vittorio Riccio; Sara Parola; Milena Casula; Panagiotis Paliogiannis; Antonio Cossu; Ursula Maria Vogl; Davide Bosso; Mario Rosanova; Brunello Mazzola; Bruno Daniele; Giuseppe Palmieri; Giovannella Palmieri Journal: Int J Mol Sci Date: 2021-07-02 Impact factor: 5.923